Contact Me for a Free Consultation [email protected]

Case Results

Prevnar 13®

As virtual in-house counsel to Wyeth Vaccines, provided on-site patent counsel services for their NC-based research and manufacturing facilities, including seminal patent prosecution and worldwide portfolio management services for Prevnar 13® (the world's best-selling vaccine before COVID-19, with over $55 Billion in sales since 2010). Pfizer acquired Wyeth in 2009 for $68 Billion, in large part due to Wyeth's vaccine and biologics portfolios. Selected patent application samples are provided below.

WO2008079732.pdf
WO2008079732 - MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION (produced multiple issued patents around the world including US Patent Nos. 7709001, 7955605, and 8895024).
WO2008045852.pdf
WO2008045852 - PURIFICATION OF STREPTOCOCCUS PNEUMONIAE TYPE 3 POLYSACCHARIDES (produced multiple issued patents around the world including US Patent No. 7659090).
WO2006110352.pdf
WO2006110352 - SEPARATION OF CONTAMINANTS FROM STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE BY PH MANIPULATION (produced multiple issued patents around the world including US Patent No. 7718791).

Contact Me

EIPL_20New_20Logo_2010-24-3.jpg

I'm happy to schedule a free 15-minute consultation to discuss your IP needs.

Whether you're a tinkerer who's come up with a new gadget or the CEO of a start-up that doesn't yet have the budget for a full-time in-house IP attorney, schedule a call.

The content of this website is for informational purposes only. The information provided herein is not intended as legal advice or as a legal opinion, and does not create an attorney-client relationship with website visitors. Readers of the website or of any linked websites should not act upon any information in them without first obtaining professional counsel on the subject matter. Every case or matter is unique with its own facts and applicable law, and success in prior cases or matters does not guarantee a similar outcome in another case or matter.

Menu